Sökresultat
12 miljoner till forskning inom cancer, stroke och Parkinson
…ägda av Mats Paulssons stiftelse för forskning, innovation och samhällsbyggande, www.mediconvillage.se. ——————————————————————————————————————————————— Lista över 2020 års anslag Mats Paulssons stiftelse för forskning, innovation och samhällsbyggande Projekt: Omprogrammering av celler för immunoterapi mot cancer Beviljat anslag: 2 miljoner kronor Huvudsökande: Filipe Pereira, universitetslektor, Medicinska fakulteten, Lunds universitet Sammanfattn…
AlzeCure presenterar nya data på IASP 2024
…d Congress on Pain by Pontus Forsell, project leader and Head of Discovery and Research at AlzeCure. The other authors include Gunnar Nordvall, Maria Backlund, Veronica Lidell, Azita Rasti, Cristina Parrado-Fernandez, Johan Sandin and Märta Segerdahl. The presentation includes new preclinical results describing the properties of the recently selected drug candidate for TrkA-NAM, ACD137. The data show that the substance is a potent and selective ne…
Höga doser av ADHD-medicin ökar risken för psykos och mani
…centage among those exposed to any prescription amphetamine was nearly 63% and for high dose amphetamine was 81%. These findings suggest that among people who take prescription amphetamine, 81% of cases of psychosis or mania could have been eliminated if they were not on the high dose. While a significant dose-related risk increase was seen in patients taking high doses of amphetamine, no significant risk increase was seen with methylphenidate (Ri…
Nytt test förutspår demens upp till 9 år före klinisk diagnos
…shed in Nature Mental Health. https://www.nature.com/articles/s44220-024-00259-5 *UKB data access was funded by a grant from the Tom and Sheila Springer Charity….
Data publicerade på AAN visar att Biogens MS-portfölj har positiv effekt på MS-patienters liv
…enters in Europe and the U.S. to help transform patient care by generating standardized data from a diverse, real-world patient population. Additionally, results from two new analyses investigating EID with natalizumab may help further inform the drug’s benefit-risk profile. Biogen continues to evaluate the efficacy, safety and tolerability of natalizumab EID through the prospective NOVA trial (NCT03689972) with initial results expected in 2021. …